Excision of tumor/mastectomy

PROCEDURE2 trials

Sponsors

Dana-Farber Cancer Institute, Shandong Cancer Hospital and Institute

Conditions

Breast CancerHER-2 Positive Breast CancerStage II Breast CancerStage III Breast Cancer

Phase 2

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Active, not recruitingNCT02326974

Dana-Farber Cancer InstituteBreast Cancer, HER-2 Positive Breast Cancer, Stage II Breast Cancer +1

Start: 2015-01-01End: 2028-01-01Updated: 2026-04-17

Unknown Phase

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

Not yet recruitingNCT07187752

Shandong Cancer Hospital and InstituteBreast Cancer

Start: 2025-09-30End: 2027-06-30Target: 1039Updated: 2025-09-23

Related Papers

HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

Journal of Clinical Investigation2024-02-0121 citations

HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.

Journal of Clinical Oncology2019-05-2081 citations